This filing is routine and contains no new financial data or restatements. Monitor the next 10-Q for any operational or financial updates, particularly regarding the Antev acquisition and ongoing clinical development programs.
Price Chart
Executive Summary
Medicus Pharma Ltd. filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive compensation, security ownership, related transactions, and auditor fees) that was omitted from the original filing. The amendment does not restate financials or modify any previously reported financial position, results of operations, or cash flows. This is a routine administrative filing with no material financial impact.
Key Facts
- Amendment adds Part III (Items 10-14) previously omitted from the Original Form 10-K filed March 25, 2026
- No restatement or modification of financial statements, results of operations, or cash flows
- New Sarbanes-Oxley Section 302 and 906 certifications filed as exhibits
- Board consists of 9 directors, 8 of whom are independent; Dr. Raza Bokhari is the sole non-independent director
- CEO Dr. Raza Bokhari total compensation for FY2025: $632,677 (all option-based and other compensation, no salary)
- CFO Carolyn Bonner total compensation for FY2025: $423,651 (salary $310,000 plus option awards and other compensation)
- As of April 15, 2026: 41,818,092 common shares outstanding; aggregate market value at June 30, 2025 was ~$28.3 million
- 5% holder: Dr. Kenneth Melani beneficially owns 3,323,741 shares (7.9%)
- Audit fees for FY2025: $724,392 (KPMG LLP); FY2024: $168,000 (EisnerAmper LLP)
- D&O liability insurance premium for FY2025: $698,792 with $10M coverage limit
Financial Impact
No financial impact — this is a purely administrative amendment adding governance and compensation disclosures.
Risk Factors
- No new financial risks disclosed beyond those in the original 10-K
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001062993-26-002212 |
| Exhibit: exhibit31-2.htm | 0001062993-26-002212 |
| Exhibit: exhibit31-1.htm | 0001062993-26-002212 |
| Exhibit: exhibit32-2.htm | 0001062993-26-002212 |
| Exhibit: exhibit32-1.htm | 0001062993-26-002212 |
| Document: 0001062993-26-002212-index-headers.html | 0001062993-26-002212 |
| Document: 0001062993-26-002212-index.html | 0001062993-26-002212 |
| Document: 0001062993-26-002212.txt | 0001062993-26-002212 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 27, 2026 21w ago | 8-K | $0.6795 $0.6795 | · 0.00% | ▲ +0.32% | — |
Apr 29, 2026 25w ago | 10-K/A | $0.6795 $0.6795 | · 0.00% | ▼ −1.73% | — |
Apr 24, 2026 26w ago | 8-K | $0.6795 $0.6795 | ▲ +0.00% | ▲ +0.40% | — |
Mar 30, 2026 30w ago | EFFECT | $0.6795 $0.6795 | ▲ +0.00% | ▲ +4.30% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers